WEST LAFAYETTE, IN--(Marketwire - May 15, 2012) - BASi (Bioanalytical Systems Inc.) (NASDAQ: BASI) has named David Reynolds as its director of discovery services. Reynolds will oversee studies and staff of the company’s new Discovery Center at corporate headquarters in West Lafayette, Ind.
Reynolds joins BASi with more than 25 years of experience in guiding drug metabolism, bioanalytical, pharmacokinetic and dispositional research, with a focus on developing new and meaningful therapeutic agents. He developed extensive experience as a study director for several major pharmaceutical companies before working as a consultant, who assisted clients in moving their compounds from discovery through IND/NDA submissions.
“David adds depth and broad experience to our discovery team,” said John Devine, vice president of nonclinical services. “We plan to leverage his expertise in study design to provide clients with quality, decisive data.”
In January, BASi opened its West Lafayette-based Discovery Center to help pharmaceutical and biotech companies develop the information they need to evaluate new compounds in the earliest stages of development. Some studies utilize the Culex® automated in vivo sampling system which provides multiple streams of data from stress-reduced subjects and allows for rapid decisions based on more accurate information. In addition to serving clients, the discovery team has conducted several in-house studies involving cutting edge brain and intestinal microdialysis techniques which will be published at upcoming professional conferences.
“BASi provides a level of expertise with in vivo sampling tools that can provide specialized Pharmacokinetic/Pharmacodynamic (PK/PD) and formulation support,” Reynolds said. “I look forward to opening up new collaborative opportunities with companies that are trying to develop new and exciting therapeutic treatments.”
About BASi
BASi is a drug discovery and development services company providing contract research services and instruments to the world’s leading pharmaceutical companies and medical research organizations. The company, based in the Purdue Research Park, focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new and generic drugs to market. Visit www.BASInc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.
